These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 18824456

  • 21. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards.
    Espinel-Ingroff A, Bartlett M, Chaturvedi V, Ghannoum M, Hazen KC, Pfaller MA, Rinaldi M, Walsh TJ.
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1828-35. PubMed ID: 11353633
    [Abstract] [Full Text] [Related]

  • 22. Susceptibility to five antifungals of Aspergillus fumigatus strains isolated from chronically colonised cystic fibrosis patients receiving azole therapy.
    Amorim A, Guedes-Vaz L, Araujo R.
    Int J Antimicrob Agents; 2010 Apr; 35(4):396-9. PubMed ID: 20138740
    [Abstract] [Full Text] [Related]

  • 23. Post-antifungal effect of amphotericin B and voriconazole against germinated Aspergillus fumigatus conidia.
    Chryssanthou E, Loebig A, Sjölin J.
    J Antimicrob Chemother; 2008 Jun; 61(6):1309-11. PubMed ID: 18367461
    [Abstract] [Full Text] [Related]

  • 24. Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus.
    Manavathu EK, Abraham OC, Chandrasekar PH.
    Clin Microbiol Infect; 2001 Mar; 7(3):130-7. PubMed ID: 11318811
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints.
    Verweij PE, Howard SJ, Melchers WJ, Denning DW.
    Drug Resist Updat; 2009 Dec; 12(6):141-7. PubMed ID: 19879181
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
    Singh J, Rimek D, Kappe R.
    Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients.
    Dannaoui E, Meletiadis J, Tortorano AM, Symoens F, Nolard N, Viviani MA, Piens MA, Lebeau B, Verweij PE, Grillot R, And The Ebga Network.
    J Med Microbiol; 2004 Feb; 53(Pt 2):129-134. PubMed ID: 14729934
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.
    Shivaprakash MR, Geertsen E, Chakrabarti A, Mouton JW, Meis JF.
    Mycoses; 2011 Sep; 54(5):e583-9. PubMed ID: 21518026
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.